Pioglitazone and alogliptin combination therapy in type 2 diabetes: A pathophysiologically sound treatment

Medicine and Dentistry

• Maturity Onset Diabetes of the Young 100%
• Hemoglobin A1c 75%
• Monotherapy 75%
• Alogliptin 75%
• Hypoglycemia 50%
• Cell Function 50%
• Pioglitazone 50%
• Insulin Resistance 50%
• Insulin Release 50%
• Beta Cell 50%
• Dipeptidyl Peptidase-4 Inhibitor 50%
• Alogliptin Plus Pioglitazone 50%
• Cells 50%
• Therapeutic Procedure 50%
• Cardiovascular System 25%
• Glucose 25%
• Drug Therapy 25%
• Glucagon Like Peptide 1 25%
• Combination Therapy 25%
• Glycated Hemoglobin 25%
• Adverse Event 25%
• Glucagon 25%
• Pancreatic Islet 25%
• Insulin Sensitizing Agent 25%
• Glucagon Release 25%
• Health 25%
• Plasma 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Insulin Dependent Diabetes Mellitus 100%
• Monotherapy 75%
• Hemoglobin A1c 75%
• Alogliptin 75%
• Insulin Resistance 50%
• Pioglitazone 50%
• Hypoglycemia 50%
• Dipeptidyl Peptidase IV Inhibitor 50%
• Alogliptin Plus Pioglitazone 50%
• Glucagon-Like Peptide-1 25%
• Adverse Event 25%
• Combination Therapy 25%
• Insulin 25%
• Tolerability 25%
• Glucose 25%
• Insulin Sensitizing Agent 25%
• Glucagon 25%
• Glycosylated Hemoglobin 25%